Effect of rutin on warfarin anticoagulation and pharmacokinetics of warfarin enantiomers in rats

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 4, 2009, Pages 451-458

  Chan, Eli ^a   Hegde, Akhil ^a   Chen, Xin ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Pharmacodynamics; Pharmacokinetics; Rutin; Stereoselective drug interactions; Warfarin

Indexed keywords

PROTHROMBIN COMPLEX; RUTOSIDE; WARFARIN; ANTICOAGULANT AGENT; PLASMA PROTEIN; QUERCETIN;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; ENANTIOMER; IN VITRO STUDY; KIDNEY CLEARANCE; MALE; NONHUMAN; OXIDATION; PROTEIN BINDING; RAT; REDUCTION; SINGLE DRUG DOSE; ANIMAL; BLOOD CLOTTING; DRUG INTERACTION; METABOLISM; SPRAGUE DAWLEY RAT; STEREOISOMERISM;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD PROTEINS; DRUG INTERACTIONS; MALE; PROTEIN BINDING; QUERCETIN; RATS; RATS, SPRAGUE-DAWLEY; RUTIN; STEREOISOMERISM; WARFARIN;

EID: 85047681120     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.04.0006     Document Type: Article

References (56)

1. Breckenridge A et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974; 15: 424-430.
2. Yacobi A, Levy G. Pharmacokinetics of the warfarin enantiomers in rats. J Pharmacokinet Biopharm 1974; 2: 239-255.
3. Lewis RJ et al. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 1974; 53: 1607-1617.
4. Rettie AE et al. Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab Dispos 1989; 17: 265-270.
5. Wells PS et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121: 676-683.
6. Harder S, Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996; 30: 416-444.
7. Zhou S, Chan E. Effect of ubidecarenone on warfarin anticoagulation and pharmacokinetics of warfarin enantiomers in rats. Drug Metabol Drug Interact 2001; 18: 99-122.
8. Zhou Q et al. Effect of omeprazole on the hydroxylation of warfarin enantiomers in human: in-vitro studies with liver microsomes and cDNA-expressed cytochrome P450 isozymes. Curr Drug Metab 2005; 6: 399-411.
9. Zhou Q et al. Effect of coenzyme Q10 on warfarin hydroxylation in rat and human liver microsomes. Curr Drug Metab 2005; 6: 67-81.
10. Sutfin T et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11: 176-184.
11. O'Reilly RA et al. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 1992; 51: 656-667.
12. Awni WM et al. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clin Pharmacokinet 1995; 29(Suppl 2): 67-76.
13. Niopas I et al. The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans. Eur J Clin Pharmacol 1999; 55: 399-404.
14. Matsumoto K et al. The stereoselective effects of bucolome on the pharmacokinetics and pharmacodynamics of racemic warfarin. J Clin Pharmacol 2001; 41: 459-464.
15. Zhou Q, Chan E. Effect of omeprazole on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats. Eur J Pharm Sci 2003; 20: 439-449.
16. Manach C et al. Quercetin metabolites in plasma of rats fed diets containing rutin or quercetin. J Nutr 1995; 125: 1911-1922.
17. Lauro MR et al. Fast- and slow-release tablets for oral administration of flavonoids: rutin and quercetin. Drug Dev Ind Pharm 2002; 28: 371-379.
18. Petruzzellis V et al. Oxerutins (Venoruton): efficacy in chronic venous insufficiency - a double-blind, randomized, controlled study. Angiology 2002; 53: 257-263.
19. Cesarone MR et al. Flight microangiopathy on long-haul flights: prevention of edema and microcirculation alterations with Venoruton. Clin Appl Thromb Hemost 2003; 9: 109-114.
20. Schmidt H et al. Investigations on capillary fragility and the effect of rutin therapy. Dtsch Med Wochenschr 1950; 75: 790-794.
21. Levitan BA. Clinical observations on the effects of injectable rutin, esculin, adrenoxyl, and vitamin E on the capillary fragility of diabetic retinopathy. Am J Med Sci 1951; 221: 185-190.
22. Volpi I. The hemostatic and vasoprotective effect of combined thromboplastin and quercetin in obstetrics and gynecology. Minerva Ginecol 1959; 11: 210-212.
23. Gryglewski RJ et al. On the mechanism of antithrombotic action of flavonoids. Biochem Pharmacol 1987; 36: 317-322.
24. Cesarone MR et al. Prevention of edema and flight microangiopathy with Venoruton (HR), (0-[beta-hydroxyethyl]-rutosides) in patients with varicose veins. Angiology 2005; 56: 289-293.
25. Bamigboye AA, Hofmeyr GJ. Interventions for leg edema and varicosities in pregnancy. What evidence? Eur J Obstet Gynecol Reprod Biol 2006; 129: 3-8.
26. Lund F et al. Intravenous hydroxyethylrutosides combined with long-term oral anticoagulation in atherosclerotic nonreconstructable critical leg ischemia: a retrospective study. Angiology 1999; 50: 433-445.
27. Andre C et al. Prevention of deep venous thrombosis and pulmonary embolism following stroke: a systematic review of published articles. Eur J Neurol 2007; 14: 21-32.
28. Wang H, Joseph JA. Structure-activity relationships of quercetin in antagonizing hydrogen peroxide-induced calcium dysregulation in PC12 cells. Free Radic Biol Med 1999; 27: 683-694.
29. Urios P et al. Flavonoids inhibit the formation of the cross-linking AGE pentosidine in collagen incubated with glucose, according to their structure. Eur J Nutr 2007; 46: 139-146.
30. Erlund I et al. Bioavailability of quercetin from berries and the diet. Nutr Cancer 2006; 54: 13-17.
31. Friel H, Lederman H. A nutritional supplement formula for influenza A (H5N1) infection in humans. Med Hypotheses 2006; 67: 578-587.
32. Moon YJ et al. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 2006; 20: 187-210.
33. Sampson L et al. Flavonol and flavone intakes in US health professionals. J Am Diet Assoc 2002; 102: 1414-1420.
34. Shimoi K et al. Absorption and urinary excretion of quercetin, rutin, and alphaG-rutin, a water soluble flavonoid, in rats. J Agric Food Chem 2003; 51: 2785-2789.
35. Erlund I et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 2000; 56: 545-553.
36. Dangles O et al. Binding of flavonoids to plasma proteins. Methods Enzymol 2001; 335: 319-333.
37. Ho PC et al. Inhibition of human CYP3A4 activity by grape-fruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 2001; 4: 217-227.
38. Hayeshi R et al. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. Eur J Pharm Sci 2006; 29: 70-81.
39. Hermodson A. 4-Hydroxycoumarins. Synthesis of the metabolites and some other derivatives of warfarin. J Med Chem 1971; 14: 167-169.
40. Bush E, Trager WF. High-yield synthesis of warfarin and its phenolic metabolites: new compounds. J Pharm Sci 1983; 72: 830-831.
41. Chan E et al. Warfarin metabolites: stereochemical aspects of protein binding and displacement by phenylbutazone. Chirality 1993; 5: 610-615.
42. Lowry OH et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
43. Zhou Q, Chan E. Accuracy of repeated blood sampling in rats: a new technique applied in pharmacokinetic/pharmacodynamic studies of the interaction between warfarin and co-enzyme Q10. J Pharmacol Toxicol Methods 1998; 40: 191-199.
44. Banfield C, Rowland M. Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine. J Pharm Sci 1984; 73: 1392-1396.
45. Chan E et al. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther 1994; 56: 286-294.
46. Banfield C et al. Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. Br J Clin Pharmacol 1983; 16: 669-675.
47. Zhou Q, Chan E. Effect of 5-fluorouracil on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats. Eur J Pharm Sci 2002; 17: 73-80.
48. Kamada C et al. Attenuation of lipid peroxidation and hyperlipidemia by quercetin glucoside in the aorta of high cholesterol-fed rabbit. Free Radic Res 2005; 39: 185-194.
49. Castilla P et al. Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects. Am J Clin Nutr 2006; 84: 252-262.
50. Chien JT et al. Kinetic model for studying the effect of quercetin on cholesterol oxidation during heating. J Agric Food Chem 2006; 54: 1486-1492.
51. Martin GJ, Swayne V. Effectiveness of vitamin P compounds in counteracting anticoagulant action of dicoumarol. Science 1949; 109: 201-202.
52. Boulton DW et al. Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol 1998; 50: 243-249.
53. Zsila F et al. Probing the binding of the flavonoid, quercetin to human serum albumin by circular dichroism, electronic absorption spectroscopy and molecular modelling methods. Biochem Pharmacol 2003; 65: 447-456.
54. Dufour C, Dangles O. Flavonoid-serum albumin complexation: determination of binding constants and binding sites by fluorescence spectroscopy. Biochim Biophys Acta 2005; 1721: 164-173.
55. Pohl LR et al. Warfarin: stereochemical aspects of its metabolism in vivo in the rat. Res Commun Chem Pathol Pharmacol 1976; 15: 233-256.
56. He N, Edeki T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther 2004; 11: 206-212.